Compare COLL & CNXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COLL | CNXN |
|---|---|---|
| Founded | 2002 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2015 | 1998 |
| Metric | COLL | CNXN |
|---|---|---|
| Price | $49.40 | $60.63 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $47.50 | N/A |
| AVG Volume (30 Days) | ★ 531.1K | 83.8K |
| Earning Date | 11-06-2025 | 02-04-2026 |
| Dividend Yield | N/A | ★ 0.98% |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.63 | ★ 3.24 |
| Revenue | $757,067,000.00 | ★ $2,878,704,000.00 |
| Revenue This Year | $26.35 | $5.85 |
| Revenue Next Year | $3.67 | $4.52 |
| P/E Ratio | $30.08 | ★ $18.81 |
| Revenue Growth | ★ 26.34 | 3.19 |
| 52 Week Low | $23.23 | $54.97 |
| 52 Week High | $49.49 | $75.08 |
| Indicator | COLL | CNXN |
|---|---|---|
| Relative Strength Index (RSI) | 71.50 | 56.95 |
| Support Level | $47.83 | $58.95 |
| Resistance Level | $49.49 | $61.45 |
| Average True Range (ATR) | 1.34 | 1.29 |
| MACD | -0.19 | 0.32 |
| Stochastic Oscillator | 87.20 | 75.12 |
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
PC Connection Inc is a provider of information technology solutions. It provides products such as computer systems, software and peripheral equipment, networking communications, and other products and accessories that company purchase from manufacturers and distributors. The company also offers services involving design, configuration, and implementation of IT solutions. It conducts business operations through three business segments namely Connection Business Solutions, Connection Enterprise Solutions, and Connection Public Sector Solutions. The company generates maximum revenue Connection Enterprise Solutions segment.